MoonLake Immunotherapeutics

NasdaqCM MLTX

MoonLake Immunotherapeutics Market Capitalization on January 14, 2025: USD 2.93 B

MoonLake Immunotherapeutics Market Capitalization is USD 2.93 B on January 14, 2025, a -19.02% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

MoonLake Immunotherapeutics 52-week high Market Capitalization is USD 4.01 B on February 12, 2024, which is 36.77% above the current Market Capitalization.
MoonLake Immunotherapeutics 52-week low Market Capitalization is USD 2.41 B on June 21, 2024, which is -17.70% below the current Market Capitalization.
MoonLake Immunotherapeutics average Market Capitalization for the last 52 weeks is USD 3.04 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: MLTX

MoonLake Immunotherapeutics

CEO	Dr. Jorge Santos da Silva
IPO Date	Oct. 20, 2020
Location	Switzerland
Headquarters	Dorfstrasse 29
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Key trends

Past 5 years